Home » Investors » Press Releases » Publication of Interim Report January – June 2022

Single Press release

Publication of Interim Report January – June 2022

August 24, 2022 5:00 am
Regulatory
Interim report

Strong sales despite external challenges

BICO Group AB 559050-5052 (NASDAQ STOCKHOLM: BICO)

BICO is the future of life-saving treatments. We are reducing the organ shortage and speeding up drug development by providing accessible life science solutions that combine biology and technology.

APRIL – JUNE 2022
(COMPARED WITH APRIL – JUNE 2021)

  • Net sales amounted to MSEK 537.6 (293.1), which corresponds to an increase of 83% (628) compared to the corresponding period previous year.
  • Organic growth for the period amounted to 7% (95).
  • EBITDA amounted to MSEK -62.9 (10.6), corresponding to a margin of -11.7% (3.6).
  • Adjusted EBITDA amounted to MSEK 11.1 (21.5), corresponding to a margin of 2.1% (7.3)
  • Net profit/loss for the period amounted to MSEK 43.1 (-50.5), corresponding to earnings per share before and after dilution of SEK 0.68 (-0.89).
  • The gross margin amounted to 73.0% (69.1). The gross margin structure in the acquired companies 2021 varies depending on the product mix.

JANUARY – JUNE 2022
(COMPARED WITH JANUARY – JUNE 2021)

  • Net sales amounted to MSEK 1,014.8 (422.6), which corresponds to an increase of 140% (440) compared to the corresponding period previous year.
  • Organic growth for the period amounted to 21% (79).
  • EBITDA amounted to MSEK -82.3 (-24.3), corresponding to margin of -8.1% (-5.8).
  • Adjusted EBITDA amounted to MSEK 17.1 (8.7), corresponding to a margin of 1.7% (2.1).
  • Net profit/loss for the period amounted to MSEK -0.4 (-98.3), corresponding to earnings per share before and after dilution of SEK 0.00 (-1.78).
  • The gross margin amounted to 73.4% (72.5). The gross margin structure in the acquired companies 2021 varies depending on the product mix.

“The company pulse is strong. We have a tremendous portfolio of products and services that contribute to the future of life-saving treatments.” ERIK GATENHOLM / PRESIDENT & CEO

Q2 KEY TAKEAWAYS

  • Highest turnover ever
  • Cash flow improvement measures
  • Strengthened finance processes
  • Continued success in innovation
  • Focus on operational efficiency and acquisition synergies
  • Cost reduction program decided after the end of the period

INVITATION TO PRESENTATION:
Join us for combined presentation audiocasts and telephone conferences with the opportunity to ask questions at 09:00 CEST and 16:00 CEST on August 24, 2022, with President & CEO Erik Gatenholm and Interim CFO Mikael Engblom.

The presentation audiocasts will be accessible via the following links:
Morning audiocast, at 09:00 CEST:
https://tv.streamfabriken.com/bico-q2-2022-am

To participate via telephone, please call any of the following numbers:
SE: +46 8 505 163 86
UK: +44 203 198 4884
US: +1 412 317 6300

PIN for all numbers: 3144420#

Afternoon audiocast, at 16:00 CEST:
https://tv.streamfabriken.com/bico-q2-2022-pm

To participate via telephone, please call any of the following numbers:
SE: +46 8 505 163 86
UK: +44 203 198 4884
US: +1 412 317 6300

PIN for all numbers: 3505431#

The presentation will also be available on the company’s website:
https://bico.com/investors/financials/financial-reports-and-presentations/

Contact us!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.